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ImmunotherapyProtein misfolding disorders, including the neurodegenerative conditions Alzheimer's disease (AD) and
Parkinson's disease (PD) represent one of the major medical challenges or our time. The underlying molecular
mechanisms that govern protein misfolding and its links with disease are very complex processes, involving
the formation of transiently populated but highly toxic molecular species within the crowded environment of
the cell and tissue. Nevertheless, much progress has been made in understanding these events in recent years
through innovative experiments and therapeutic strategies, and in this review we present an overview of the
key roles of antibodies and antibody fragments in these endeavors. We discuss in particular how these species
are being used in combination with a variety of powerful biochemical and biophysical methodologies, including
a range of spectroscopic and microscopic techniques applied not just in vitro but also in situ and in vivo, both to
gain a better understanding of the mechanistic nature of protein misfolding and aggregation and also to design
novel therapeutic strategies to combat the family of diseases with which they are associated. This article is part
of a Special Issue entitled: Recent advances in molecular engineering of antibody.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Protein misfolding, amyloid deposition and disease
A wide range of human pathologies, including Alzheimer's disease
(AD), Parkinson's disease (PD), Huntington's disease (HD), Creutzfeld
Jacob disease (CJD), type II diabetes, amytrophic lateral sclerosis (ALS)
and a variety of systemic amyloidoses are linked to the conversion of
disease-speciﬁc proteins from their soluble state into highly ordered
β-sheet rich ﬁbrillar amyloid structures [1–6]. These disorders, known
variously as protein misfolding aggregation, conformational or deposi-
tion diseases, have major human and economic costs to society.
All these diseases are characterized by the conversion of a normally
soluble and functional protein into insoluble and pathogenic protein
deposits in a variety of organs or tissues. When these disorders were
originally investigated, the observation that affected tissue could be's disease; HD, Huntington's dis-
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brain barrier
dvances in molecular engineer-
. This is an open access article understained with iodine, led to the misconception that the deposits were
rich in starch, leading to their common name as amyloid (starch-like)
deposits [7]. Amyloid deposits are, however, largely composed of pro-
teinmolecules that have aggregated into ﬁbrillar species rich in ordered
β-sheet structure. Each disease is associated with one or more speciﬁc
proteins, e.g., Amyloid-β (Αβ) peptide or tau protein in Alzheimer's dis-
ease (AD), mutant forms of huntingtin (mHTT) in Huntington's disease
(HD),α-synuclein (aSyn) in Parkinson's disease (PD), β2-microglobulin
(β2m) in dialysis-related amyloidosis (DRA) and the human prion pro-
tein (hPrP) in Creutzfeld–Jacob Disease (CJD) [4].1.1. Mechanism of the formation of protein amyloid ﬁbrils
It is nowwell established that the ability to form amyloid structures
is not limited to the small subset of proteins or peptides that are
involved in disease, but that any protein can in principal adopt this
structural state [8–11]. The relative propensity of different proteins to
convert into the amyloid state vary signiﬁcantly, however, and depends
on the overall thermodynamic stability of the native state of the protein
as well as on the kinetic accessibility of partially folded intermediates
that initiate the amyloid formation cascade [11,12]. The latter factor
determines the frequency at which such conformations are sampled
by a protein and thus the rate at which the protein is able to form ﬁbrils
under given conditions. Changes in the stability of speciﬁc proteins bythe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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presence of destabilizing mutations, may allow amyloidogenic species
to be sampled more frequently, thereby initiating the amyloid ﬁbril
formation process more readily [11,12].
Themolecularmechanisms of the amyloid formation cascade and its
associated toxicity have been extensively investigated in vitro and
in vivo for a number of different proteins [13–20]. These studies
have led to the realization that the ready formation of the amyloid
form of proteins involves several key steps. Initially, a protein species
with a high propensity for self-association needs to be formed, for
example as a result of the exposure of hydrophobic residues; such
species can be partially unfolded intermediates populated on the fold-
ing or unfolding pathways of globular proteins, or partially folded
aggregation-prone members of the ensemble of structures in intrinsi-
cally disordered proteins [20]. In subsequent steps, these aggregation-
prone species self-assemble into a variety of oligomeric species that
convert into highly organizedmature ﬁbrils through a series of complex
steps, typically involving primary nucleation, conformational rear-
rangement, aggregate growth and fragmentation, and secondary nucle-
ation through surface mediated catalysis [11]. The kinetics of such
underlying microscopic process of protein amyloid formation can now
be analyzed and dissected using well-deﬁned simple reaction schemes,
such as those outlined in Fig. 1 [21–23]. These models allow accurate
determination of the microscopic rate constants of the various primary
and secondary processes involved in a given aggregation reaction from
appropriate experimental measurements, and in addition provide the
opportunity for the design and screenings of potential drugs that can
perturb the speciﬁc microscopic events [3].
The resulting ﬁbrillar structures have “generic” features, such as a
characteristic “cross-β” structure, which can be readily established
through X-ray ﬁber diffraction studies, and the ability to bind dyes such
as Congo Red or Thioﬂavin T [24]. The basis for these generic features of
amyloid ﬁbrils can be found in the fact that the atomic interactions that
stabilize the β-sheet structures of ﬁbrils are primarily mediated through
backbone atoms of polypeptide chains [11]. In contrast, the structures of
the native states of globular proteins are determined by speciﬁc side-
chain interactions that are characteristic of their unique individual se-
quences [25,26]. Indeed, as mentioned above, the amyloid structure can
be considered to be a generic fold, which is accessible in principle under
appropriate conditions by all proteins regardless of their sequences, al-
though the propensity to convert into this state can vary widely [26].
The toxic nature of the different misfolded species populated during
ﬁbril formation is still a matter of intense discussion. In some situations,Fig. 1.A kineticmodel of ﬁbril formation including primary and secondary processes. Solublemo
have the potential to convert into ﬁbrils. The formation of ﬁbrils is signiﬁcantly enhanced by se
addition of soluble proteinmolecules. The latter processes include fragmentation, which genera
surface functions as a template for the generation of new oligomeric species.
(Figure adapted from [22] and [23]).for example, in the case of misfolding of lysozyme, which underlies a
type of familial systemic amyloidosis [27], the ﬁbril deposits themselves
are likely to be the direct cause of the disease by inﬂicting physical
damage to vital organs; a similar situation occurs with liver damage
caused by deposition of α1-antitrypsin although in this case the
deposits are not speciﬁcally amyloid like in nature [28].
In a large number of studies, however, it is the smaller, more mobile
oligomeric species with high surface-to-volume ratios and high hydro-
phobicities that have been identiﬁed as the directmediators of cell dam-
age and cell death [17,29]. Although these small oligomeric structures
might be the most direct toxic agents, however, the presence of larger
ﬁbrils can contribute signiﬁcantly to the toxicity, as these structures
can, in at least some cases, enhance dramatically the generation
of toxic oligomers through surface catalyzed secondary nucleation
(Fig. 1). Such secondary processes may be of great importance in the
progression and spreading of Alzheimer's disease [3,23] and Parkinson's
disease [30], and their existence further underscores the importance of
designing therapeutic strategies that suppress the occurrence of speciﬁc
microscopic steps in the overall aggregation process [11].
1.2. Disease pathology: the mechanisms of cytotoxicity
As mentioned above, it is generally believed that the precursors of
ﬁbrillar deposits, particularly small oligomeric species, are important
causative agents for cellular toxicity in protein deposition diseases.
The high surface-to-volume ratios and presence of exposed hydropho-
bic residues [31] in such pre-ﬁbrillar species are very likely to trigger
aberrant behavior as a result of inappropriate interactions with cellular
components, such as transcription factors, receptors or membranes,
which can lead to high oxidative stress, or stimulate apoptosis or
other forms of cell death. The high propensity of oligomeric species to
bind to membranes, attributable to their ﬂexible, dynamic and unstable
nature, has received a great deal of attention in the literature [32–35],
and could lead to pore formation and membrane permeability, which
can in turn might lead to loss of protein homeostasis and the appropri-
ate regulation of signaling pathways.
These oligomeric species have also been found to interact inap-
propriately with a number of cell surface receptors. In the context
of AD, for example oligomeric species of the Aβ-peptide have been
reported to interact strongly with the prion protein (PrP) [36,37],
with NMDA [38,39] receptors and the associated tyrosine kinase
EphB2 [39] receptor, and a variety of other cell-surface receptors
(reviewed in [40]). Such interactions could possibly lead to aberrantnomeric forms of proteins undergo primary nucleation to generate oligomeric species that
condary processes that result in the proliferation of aggregates able to grow by the further
tes new ﬁbril ends atwhich growth occurs and surface catalyzed nucleation, inwhich ﬁbril
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microtubule formation), and the production of reactive oxygen spe-
cies (ROS) that then could eventually lead to synaptic dysfunction
and apoptosis. Although different types of oligomeric species have
been found to bind to these receptors, the identity and structural
characteristics of the species responsible for the induced cytotoxic
effects remains controversial [41]. Oligomers of the Aβ-peptide
have also been shown to accumulate and exert cytotoxicity within
the cytosol, such as proteosomal and mitochondrial dysfunction.
Accumulation of Aβ oligomers possibly occurs through their interaction
with the receptor for advanced glycation end products (RAGE) [42], the
α7 nicotinic acetylcholine receptor α7nAChR [43,44] and/or the Apo-E
[45,46] receptor.
In the case of HD, for which pathogenicity is thought to be initiated
by the aggregation of mHTT within the cell, toxicity has been attributed
to ER stress [47,48], mitochondrial dysfunction [49–51] and ROS pro-
duction [52], and also to the loss of regulation of the N-methyl-D-
aspartate receptor (NMDAR) [50] and of transcription [54] and nucleo-
lar stress [53,54]. Also loss of function resulting from the direct seques-
tration of transcription factors, including transcription factors such as
CBP [CREB (cAMP-response element binding protein)-binding protein]
[55], TATA-binding protein [56] and Sin3a [57], by nuclearmHTT aggre-
gates has been linked to the pathogenicity in HD. Also essential chaper-
ones such as the low abundant Hsp40 chaperone Sis1p have been
found to be sequestered by nuclear mHTT aggregates leading to the
impairment of the UPS –mediated degradation of misfolded proteins
[58]. In addition, it has been shown that enhanced mHTT aggregation
into ﬁbrillar structures can cause increased cell oxidative stress, sug-
gesting that the ﬁbrillar material itself could contribute directly to this
toxic mechanism [52].
In Parkinson's disease oligomeric species have also been suggested
asmajor culprits of neurodegeneration, including the direct observation
of the formation of a speciﬁc type of oligomeric species of aSyn, using
single molecule ﬂuorescence techniques, that have been shown to be
toxic [59]. The kinetics of oligomer formationwere also shown to corre-
late strongly with increased ROS levels in cultures of primary neurons,
in contrast with low levels of toxicity found for other oligomeric species
and for the ﬁbrils themselves [59]. In addition, as for the Aβ peptide
associated with AD, oligomeric species of aSyn, have also been found
to interact strongly with cellularmembranes leading to membrane per-
meabilization and interferencewith ionic-homeostasis [60,61]. Further-
more, as with Aβ oligomers, oligomeric species of aSyn have also been
shown to interact aberrantly with α4β2 nicotinic acetylcholine recep-
tors [62]. Additionally it has been shown that aSyn oligomers activate
microglia via the activation of Toll-like receptor 2 (TLR2), inducing
neuroinﬂammation and leading to enhanced neurodegeneration [63].
2. Generation of antibodies and antibody fragments
The high speciﬁcity and binding afﬁnity of antibodies have made
these species invaluable and unique tools for a vast range of biotechno-
logical and pharmaceutical applications. Before the development of hy-
bridoma technology [64], antibodies had to be produced as polyclonal
anti-sera in immunized animals, but there were already many different
applications, including passive immunizations for therapeutic purposes
pioneered by von Behring and Kitasato [65].
Hybridoma technology [64] revolutionized the ﬁeld as it allowed
relatively easy production of monoclonal antibodies and the possibility
of their manipulation and modiﬁcation, including the generation of
bispeciﬁc constructs and humanization [66]. More recently, phage-
display [66,67], ribosomedisplay [68,69] and yeast-display [70,71] tech-
nologies have further impacted the ﬁeld signiﬁcantly by allowing anti-
body fragments, including Fab and scFv domains and also nanobodies,
see below, to be selected from synthetic and naïve libraries, effectively
bypassing the immune system [72]. The microbial expression systems
allow easy and cheap production of speciﬁc antibody fragments andefﬁcient protein engineering, including in vitro afﬁnity maturation and
the generation of manifold constructs containing new functionalities
[72].
Antibody fragments, as opposed to full-length antibodies, are indeed
very attractive in many biotechnological and clinical applications that
do not require the effector functions of the complete antibodymolecule,
as they are much smaller and better expressed [73]. Moreover, these
fragments are also often found to express and function well and inside
the cell allowing intracellular bio-molecules to be targeted; the anti-
body fragment is then referred to as an intrabody (intra-cellular anti-
body fragments) [74,75]. Antibody fragments are derived from full-
length conventional antibodies and can be composed of the separate
VH [76–78] or VL [78,79] domain of the complete antibody (single-do-
main antibodies) or, more commonly, of both domains genetically
linked by a ﬂexbile Gly-Ser linker (single-chain Fv, scFv) [80].
Nanobodies are an additional important type of fragment, which have
been developed following the very surprising discovery of naturally oc-
curring antibodies in camelids that lack the light chains of conventional
antibodies (Fig. 2) [81,82]. Nanobodies are the single binding domains
of camelid heavy chain antibodies (VHH) and have comparable binding
strengths and speciﬁcities to their conventional Fv equivalents, but they
are superior in stability and solubility, allowing easy production and
manipulation [83–85]. For these reasons, nanobodies are now rapidly
emerging to become very strong competitors of conventional antibodies
and antibody fragments in biotechnology [86].
2.1. Antibodies targeted against amyloidogenic proteins
Awide range of antibodies, eithermonoclonals, or fragments obtain-
ed from phage display libraries, has been generated against a variety of
proteins and peptides involved in proteinmisfolding diseases. These in-
clude scFv's, nanobodies and VL domains and have been designed to be
used for basic immunohistochemistry, rational drug design, and disease
target validation and to explore potential therapeutic strategies. The
ﬁeld is very extensive and so in this article we will limit ourselves to
the review of studies in which antibodies have been central to the elu-
cidation of key aspects of the mechanisms of amyloid formation and
toxicity for a limited number of systems, including those relating to
AD (Aβ), PD and other synucleinopathies (aSyn), HD (mHTT), CJD and
other prion protein related diseases (PrP), dialysis related amyloidosis
and systemic amyloidosis (HuL) (Table 1). Inmany cases, the antibodies
were raised against the native monomeric form of the amyloidogenic
protein [87–92], although some polyclonals, monoclonals and antibody
fragments have been raised against oligomeric or ﬁbrillar forms of Aβ
and aSyn (see Table 1), either through immunization or through the
creation of synthetic phage-display libraries [93–99].
3. Structural and mechanistic studies of amyloid formation using
antibodies
3.1. Mechanistic insights into amyloid formation in vitro
Antibody fragments can be highly informative about the nature of
the different species formed along the aggregation pathway of an
amyloidogenic protein. Epitope accessibility and conformational
changes typically have dramatic effects on antibody binding interac-
tions, and thermodynamic analysis can offer indirect insights into
the nature of structural changes [124,125]. Antibodies that bind to dif-
ferent regions of a protein molecule allow mechanistic insights into
the structural role of these epitopes in the processes associated with
amyloid formation.
Studies of the amyloid formation by HuL illustrate this point particu-
larly clearly. HuL ﬁbril formation is initiated by the cooperative unfolding
of theβ-domain of the protein [126], which can then associatewith other
partially unfolded monomers to form oligomeric, preﬁbrillar and ﬁbrillar
species (Fig. 3). This cooperative unfolding of the β-domain is enhanced
Fig. 2. Conventional and camelid (heavy-chain) antibodies and the antigen-binding fragments derived from these.
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in theα/β interface of the protein [27,127], which reduce the overall sta-
bility of the protein as well as its global cooperativity [128]. A series of
nanobodies raised against lysozyme has been found to bind to different
epitopes on the protein [87–89,100], (Table 1) and all of these were
found to inhibit the formation of ﬁbrils, regardless of the epitope con-
cerned. It has however been shown that only the nanobodies that bind si-
multaneously to both the α − and β − domains of the protein were
capable of preventing the cooperative unfolding of the β-domain [128]
The nanobody, cAb-Hul5, however, was found to bind to the α-domain
of the protein and revealed that this domain is required to undergo a fur-
ther unfolding step in order to allow this region of the sequence to be in-
corporated into a ﬁbrillar structure (Fig. 3) [100].
For α-synuclein in contrast we have shown that nanobodies raised
against the C-terminal residues of the protein (Table 1) do not inﬂuence
dramatically the kinetics of ﬁbril formation by α-synuclein but that
binding data in combination with thermodynamic analysis can be very
informative for deciphering the subtle structural transitions that take
place during aSyn ﬁbril maturation [90,101].
In a different study, a scFvwith high afﬁnity formonomeric aSynwas
isolated from a synthetic human scFv library and shown to bind to two
different regions in the aSyn sequence, including residues 27–37 in the
N-terminal region and residues 101–111 in the C-terminal region of
the protein, but with a preference for residues 101–111 [99]. This ob-
served cross-reactivity of the scFv with different regions on the protein
is most probably due to a shared –GKxxEG- motif in both epitopes. It
was found that the antibody fragment also bound to the ﬁbrils of aSyn,
which suggests that a similar motif, either in N-terminal region or the
C-terminal region must be exposed to the solvent [99].
3.2. Structural studies of kinetically trapped amyloidogenic intermediates
Early events on the amyloid formation pathway of any protein are
likely to be extremely hard to characterize as they typically represent
high-energy states of the system, and hence are very low in popula-
tion, and can convert directly into the highly stable amyloid ﬁbril
state [11]. Obtaining any structural information on these events istherefore a major challenge using conventional techniques, such as X-
ray crystallography and NMR spectroscopy, which rely on the presence
of homogeneous and well-populated protein species. Antibody binding
can serve to trap species that are present only at lowpopulations, some-
times enabling the crystallization of the complex to provide clues as to
the nature of the intermediate species.
Indeed for the proteins β2m [123] and HuPrPc [121], nanobodies
were used in this way and have shed light on the possible mechanisms
by which nucleation of aggregate formation would occur. Domanska et
al. [123], crystallised a complex between a nanobody, Nb24 (Table 1),
and the amyloidogenic N-terminal truncated variant of β2m, ΔN6β2m,
a protein involved in dialysis related amyloidosis (DRA), a condition
that occurs in patients that undergo prolonged haemodyalis, which
causes a gradual build up β2m protein due to ineffecient permeability
of the dialysis membrane [129]. In the crystal lattice, it was observed
that two Nb24:ΔN6β2m complexes were bonded to each other to
form a hetero tetramer, and which was the result of the structural ex-
change of the C-terminal ß-stands of two ΔN6β2mmolecules. This ob-
servation led to the suggestion that a domain swapped species could be
an intermediate species in the formation of β-sheet rich ﬁbrils of β2m
[123]. This structure offers important insights into the mechanism by
which β2m forms amyloid ﬁbrils, and the structural details observed
in this study are consistent with previously published and more recent
work on the possible determinants of β2m ﬁbril formation [130–136].
In the case of HuPrPC the crystal structure of the full-length protein
in complex with the Nb484 nanobody shows how the palindromic
motif AGAAAAGA in the HuPrP, which is unstructured in solution,
forms an extended β-strand that engages with the B1 strands of the
core of the protein tomake an extendedβ-sheet [121]. This palindromic
sequence is located in the generally disordered N-terminal region of
HuPrP and is believed to play a central role in the conversion of soluble
HuPrPC into the aggregated and potentially pathogenic form of the pro-
tein HuPrPSc.
In a study of the mechanism of the aggregation of Aβ, a peptide
containing the sequence 18–41 (equivalent to the p3 α/γ-secretase
fragment of the precursor protein APP), was incorporated within the
CDR3 loop of a (shark Ig new antigen receptor (IgNAR)) single variable
Table 1
Generation of antibody fragments against amyloidogenic protein targets.
Antibody Type/isolation method Target protein/antigen Species/epitope Reference
cAb-HuL6 Nanobody/immunization & phage-display HuL/WT HuL Monomer/α/β domain and C-helix,
residues 15, 16, 20, 76–79 90, 91, 94,
95, 97, 98, 101
[88,89]
cAb-Hul22 Nanobody/immunization & phage-display HuL/WT HuL Monomer/α/β domain [87]
cAb-Hul5 Nanobody/immunization & phage-display HuL/WT HuL Monomer/α domain, residues 10, 13,
14, 16, 18, 19, 22–24, 26, 27, 121, 122,
130
[100]
NbSyn2 Nanobody/immunization & phage-display aSyn/human WT aSyn Monomer/residues 135–140 [90]
NbSyn87 Nanobody/immunization & phage-display aSyn/human aSyn A53T Monomer/residues 118–132 [101]
Syn-10H scFv/synthetic human scFv library & phage display aSyn/human WT aSyn
(oligomer and ﬁbrillar form)
Oligomer and SDS stable trimer or
hexamer/n.d.a
[52,102]
D10 scFv/synthetic human scFv library & phage display aSyn/WT aSyn Monomer/residues 27–37 and 110–121 [99,103]
D5 scFv/synthetic human scFv library & phage display aSyn/WT aSyn Oligomer and SDS stable dimer or
tetramer/n.d.a
[104]
NAC32 scFv/synthetic human scFv library & yeast display aSyn/aSyn53–87-biotin Monomer/NAC region residues 53–87 [105]
VH14 VH/synthetic human scFv library & yeast display aSyn/aSyn53–87-biotin Monomer/NAC region, residues 53–87 [105,106]
C1 scFv/synthetic human scFv library & phage display Aβ/Aβ1− 40 Monomer/residues 29–40 [107]
H1v2 scFv/synthetic human scFv library & phage display Aβ/Aβ1− 28 Monomer/residues 17–28 [107]
B6 & D4 scFv/synthetic human scFv library & phage display Aβ/Aβ25− 35 Monomer/residues 25–35 [108]
B10 Nanobody/synthetic nanobody library & phage-display Aβ/Aβ1− 40 ﬁbrils Fibrils/n.d.a [98]
E1 scFv/synthetic human scFv library & phage display Aβ/Aβ1− 42 oligomers Small oligomers/n.d.a [109,110]
A4 scFv/synthetic human scFv library & phage display Aβ/Aβ1− 42 oligomers Oligomers/n.d.a [109,110]
C6 scFv/synthetic human scFv library & phage display Aβ/brain-derived Aβ oligomers Oligomers (from brain)/n.d.a [96]
A11 Polyclonal IgG/rabbit immunization Aβ/Aβ1− 42-coated gold particles Oligomers (pan-reactive)/n.d.a [111,112]
OC Polyclonal IgG/rabbit immunization Aβ/Aβ1− 42 ﬁbrils Fibril (pan-reactive)/n.d.c [112]
Happ 1&3 VL/synthetic human scFv library & phage display HTTexon1/polyP-PQLPQPPPQAQP-PolyP Monomer/proline rich region [113]
scFvC4 scFv/synthetic human scFv library & phage display HTTexon1/HTTexon11–17-biotin Monomer/residues 5–17 [114]
VL12.3 VL/synthetic human scFv library & yeast display HTTexon1/HTTexon11–17-biotin Monomer/residues 1–20 [115,116]
MW1 mAb & scFv/mouse immunization & hybridoma HTTexon1/GST-DRPLA1–35-Q19b Monomer/polyQ region [117,118]
MW2 mAb & scFv/mouse immunization & hybridoma HTTexon1/GST-DRPLA1–35-Q19b Monomer/polyQ region [117,118]
MW5 mAb & scFv/mouse immunization & hybridoma HTTexon1/GST-DRPLA1–35-Q35b Monomer/polyQ region [117,118]
MW3,4 & 6 mAb/mouse immunization & hybridoma HTTexon1/mHTTexon1-Q67 Monomer/polyQ region [117]
MW7 mAb & scFv/mouse immunization & hybridoma HTTexon1/mHTTexon1-Q96
(+boost with ﬁbrils)
Monomer/proline rich region [117,118]
MW8 mAb & scFv/mouse immunization & hybridoma HTTexon1/mHTTexon1-Q96
(+boost with ﬁbrils)
mHTT inclusions/8 last residues
mHTTexon1
[117]
EM48 scFv/rabbit immunization & hybridoma HTTexon1/GST-HTT1–250 Monomer/HTTexon1 C-terminal region [119,120]
Nb484 Nanobody/immunization & phage display PrP/rec PrP23–231c Monomer/residues
123 − 125,164 − 170,174 − 185
[121]
POM2& 12 mAb & scFv/mouse immunization & hybridoma PrP/rec PrP23–231c Monomer/residues 57–64, 64–72,
72–80, 80–88
[122]
POM11 mAb/mouse immunization & hybridoma PrP/rec PrP23–231c Monomer/residues 64–72, 72–80 [122]
POM3 mAb/mouse immunization & hybridoma PrP/rec PrP23–231c Monomer/residues 95–100 [122]
POM5 mAb/mouse immunization & hybridoma PrP/rec PrP23–231c Monomer/β2–α2 loop, α2 residues
168–174
[122]
POM4,10& 19 mAb/mouse immunization & hybridoma PrP/rec PrP23–231c Monomer/β1 and α3, residues 121–134
and 218–221
[122]
POM1 mAb/mouse immunization & hybridoma PrP/rec PrP23–231c Monomer/β1–α1 loop, α1 and α3
138–147; residues 204/208/212
[122]
POM6,7,13,15 & 17 mAb/mouse immunization & hybridoma PrP/rec PrP23–231c Monomer/β1–α1 loop, α1 β2–α2 loop,
α2 residues 140/145; 158/177; 170/174
[122]
POM8 & 9 mAb/mouse immunization & hybridoma PrP/rec PrP23–231c Monomer/β1–α1 loop, α1 β2–α2 loop,
α2 residues140/145; 170/174
[122]
Nb24 Nanobody/immunization & phage display β2m Monomer residues 41–45, 75–77 [123]
a n.d., not determined.
b DRPLA, dentatorubral palliodoluysian atrophy.
c rec, recombinant.
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interactions between inserted regions of Aβwith paired dimers forming
a tetramer in the crystal caged within four IgNAR domains, inhibiting
further assembly into amyloid ﬁbrils [137]. The structure provided a
possible structural mechanism for Aβ17–42 oligomerization, involving a
tight arrangement of the amyloidogenic peptide into a non-cross
β-sheet tetrameric arrangement [137].
3.3. Stabilization of transiently populated oligomeric states by antibodies
As the oligomeric precursors of amyloid ﬁbrils arewidely considered
to be the most toxic species generated during the aggregation of
peptides and proteins, considerable effort is expended in their charac-
terization. This objective is, however, extremely challenging becauseof the heterogeneous and transient nature of these assemblies. More-
over, the peptides or proteins associated with amyloid diseases are
often intrinsically disordered, as is the case for the Aβ-peptides in AD
and aSyn in PD [11]. Such proteins typically adopt highly diverse and
rapidly inter-converting conformational states thatmake theuse of con-
ventional techniques, such as X-ray crystallography and NMR spectros-
copy, for the structural characterization or even the soluble precursor
states particularly demanding, although NMR techniques have made it
possible to deﬁne detailed ensembles that are representative of these
states [138]. The development of structural approaches that are highly
sensitive to structural motifs that are transiently populated are there-
fore of great signiﬁcance for investigating such species, along with the
variety of aggregated assemblies that are formed during the process of
ﬁbril formation [124]. Indeed, given the crucial role that the small highly
Fig. 3. Schematic description of the process of amyloid formation by human lysozyme and the effects of lysozyme speciﬁc conformational antibody fragments.
(Adapted from [124] and [100]).
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it is of particular importance to obtain detailed structural information
on these speciﬁc species, in order to increase our understanding of the
underlying structural and physical aspects of their formation, and of
the origin of their pathogenic nature.
The assumption of such informationwill be of key signiﬁcance for the
design of potential therapeutics based on the strategies of suppression of
their formation or the reduction in their toxicity. At presentwe know rel-
atively little about the detailed molecular structures of these crucial spe-
cies, and a wide variety of oligomeric assemblies that differ signiﬁcantly
in size and morphology can often be generated under different condi-
tions for any given protein. There is, therefore, a need for a stringent clas-
siﬁcation system for the different oligomeric species to deﬁne clearly the
origin of speciﬁc cytotoxic effects [139]. The high speciﬁcity and high af-
ﬁnity of antibodies for their antigens, could, therefore, enable them to
play a key role in this objective, as selective and extremely sensitive
probes that can discriminate between oligomers of different size and
structure [140–142]. Antibodies can, in addition, stabilize or solubilize
certain forms of aggregates, and thereby potentially allow them to bestudied bywell-established structural techniques. Thus, for example, an-
tibodies have been used very successfully to solubilize and crystallize
membrane proteins; important examples are studies of the structures
of a series of various G protein-coupled receptors [143–145].
A number of strategies have been used to generate antibodies
against toxic oligomeric species. Of particular interest have been the re-
cent reports involving the immunization of mice with gold particles
coated with Aβ, mimicking an oligomeric form of the peptide [139,
146–148], that resulted in the polyclonal antibody, A11, that has been
found to cross-react with protein oligomeric species formed from
other types of peptides and proteins (including aSyn, HTT, SOD, amyloid
light chain). These ﬁndings suggest that a generic conformational
epitope exists rather than one characterized by speciﬁc amino acid
side-chains [111]. The polyclonal A11 antibody (Table 1) that interacts
with the oligomers does not bind to the mature ﬁbrillar form of the an-
tigens, or indeed to their soluble states consistent with the hypothesis
that major structural transitions are associated with the formation of
these oligomers and that they undergo further major structural rear-
rangements upon ﬁbril formation [111].
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clonal antibodies, denoted OC (Table 1), were obtained, which interact
speciﬁcally with ﬁbrillar forms of several proteins but do not interact
with oligomeric pre-ﬁbrillar species or with monomeric Aβ [112].
Both the A11 and the OC antibodies have been widely used to distin-
guish between oligomeric and ﬁbrillar species of a range of different
proteins [139].
A combination phage-display and atomic forcemicroscopy has been
used as an alternative strategy that has enabled isolation of scFv frag-
ments from a human synthetic scFv library that bind to visualized
oligomeric or ﬁbrillar forms of Aβ and/or αSyn, with variable cross-
reactivity to other proteins [97,102,104,109,149]. It was shown that
substiochiometric quantities of these anti-oligomeric scFv's were able
to inhibit the formation of aSyn ﬁbrils, and also to suppress dramatically
the cellular toxicity of synthetically formed oligomeric species of aSyn. A
scFv against ﬁbrillar aSyn, however, cross-reactedwithﬁbrils formed by
mutant huntingtin (mHTTexon1) fragments. In this case, co-expression
of the aggregating mutant protein with the anti-ﬁbillar scFv as an
intrabody increased both the size of the intracellular aggregates and
cytotoxicity [52], and illustrates that antibody fragments targeting
toxic species of proteins can either increase or decrease toxicity.
A different approach using VH single domain antibodies against
oligomeric and ﬁbrillar forms of peptides and proteins has also been
developed and applied to Aβ, aSyn and islet amyloid polypeptide
(IAPP) [93,94]. Here the VH domain antibodies have been synthetically
designed to contain short sequences of residues from regions of the
targeted proteins that are expected to be highly amyloidogenic. These
segments are then inserted genetically into the CDR3 loop of the VH
domain antibodies, and depending on the length of the sequence that
is inserted, antibodies binding to either to oligomers or ﬁbrils is ob-
served. The resulting VH domain antibodies have been found to inhibit
effectively formation of ﬁbrils by the proteins that were targeted in this
way, and have the capacity to reduce the toxicity associated with the
oligomers[93,94].
4. In situ and in vivo studies of protein misfolding using antibodies
and antibody fragments
Protein aggregation and its underlying toxic effects occur in a very
complex environment in vivo, involvingmany different components, in-
cluding biological membranes, membrane bound receptors, molecular
chaperones andmany other biomolecules [11,150,151]. Amyloid forma-
tion is often thought to initiate within the cell, but it can then be spread
to the extracellular space and to neighboring cells [152,153]. Aggrega-
tion behavior of the peptides and proteins that have been measured
in vitro, and the consequent effects of this process, such as toxicity,
must therefore be translated into the analogous behavior in a cellular
environment and indeed in a living organism. In addition, potential
drugs discovered or developed in vitro, including antibodies and anti-
body fragments, must be examined to ensure that they are inﬂuencing
the aggregation behavior in vivo as well as in vitro. In the next section
we discuss a number of systems for which antibodies have been used
both to probe themechanismof aggregation and to explore the possibil-
ity of their use as therapeutics.
4.1. Huntington's disease
Huntington's disease (HD) is an autosomal dominant neurodegener-
ative disorder, characterized by severe motor and variable psychiatric
dysfunctions [154]. The underlying molecular origin of HD involves an
aberrant expansion of the N-terminal polyglutamine (polyQ) tracts of
the protein huntingtin (HTT) [155]. HTT is found predominantly in the
cytosol, but in HD, N-terminal proteolytic fragments encompassing
the ﬁrst exon of mutant forms of HTT (mHTTexon1), which are charac-
terized by aberrant expansions of thewild-type polyQ tract (on average
16–20 glutamines) to a polyQ tract that exceeds 36 and up to 250glutamines in mHTT, with an inverse correlation of both onset of
motor symptoms and age of death with the polyQ repeat length in HD
subjects [155–157]. ThesemHTTexon1 fragments are found to accumu-
late as insoluble inclusions in cellular nuclei [158,159]. A number of an-
tibodies and antibody fragments that bind to mHTTexon1 have been
isolated, some of which can be expressedwithin different cell-types, in-
cluding neuroblastoma, human embryonic kidney or striatal cells as sol-
uble intrabodies (Table 1) [52,99,113–115,117,118,160–162]. It is now
apparent that the ability of anti-mHTTexon1 intrabodies to modulate
aggregation and its associated neurotoxicity strongly depends on the
epitope of HTT toward which they are directed [163].
A 17-residue sequence denoted HTT(1–17) is located immediately
N-terminal to the polyQ tract inHTT, and has been shown to be involved
in membrane binding and sub-cellular localization, as well as being
associated with aggregation and toxicity [164–172]. The sequences
ﬂanking polyQ at its C- and N-terminal region have opposite effects on
the kinetics of the aggregation of mHTTexon1 fragments when studied
in vitro [173]. The key role of the HTT(1–17) sequence in the pathogenic
deposition of mHTT aggregates and its inhibition by molecular chaper-
ones that bind to this region [174] make it a very attractive target for
the development of intrabodies able to suppress mHTTexon1 aggrega-
tion [163]. Two intrabodies have so far been reported that bind to this
region, VL12.3 [115,116,175] and scFvC4 [114,160], and both antibody
fragments have been found to bind to the N-terminal residues of
HTTexon1 preceding the polyQ region and to reduce very potently
mHTTexon1-induced aggregation and toxicity in vitro and in situ,
while not altering signiﬁcantly the turnover of mHTT [73,114,160].
The VL12.3 appears, however, to block the retention of mHTTexon1 in
the cytoplasm, and indeed to give rise to much higher levels of the
antigen-antibody complex in the nucleus,[113,176] a compartment
that is known to be a major site of mHTT pathogenesis. When VL12.3
is delivered directly to HTT transgenic mouse brains via gene therapy,
there is also a slight increase in disease severity [176]. By contrast, the
complexes of scFvC4 and mHTTexon1 show signiﬁcant localization in
the cytoplasm, and reduce the aggregation phenotype when delivered
as genes ([177] and Butler et al, in prep). To counteract the long-term
kinetic effects of aggregation in vivo, scFvC4 was engineered to include
a fusion to a proteosomal degradation sequence, with enhanced protec-
tive effects in situ [178]. These studies therefore underscore the impor-
tance of validation of speciﬁc targets in a cellular context.
In a study that was aimed at developing immunohistochemistry re-
agents for HDpathology, eightmonoclonal antibodies,MW1–8, binding
to the polyQ tract or to the C-terminal regions ofmHTTexon1were gen-
erated [117]. The mAbs MW1–6, were obtained by immunizing Balb/c
mice using a number of soluble GST fusion proteins containing polyQ
sequences of different lengths. The mAbs MW7–8 were obtained
usingﬁbrillar forms ofmHTTexon1 in the boosting steps of the immuni-
zation [117,179]. The mAbs MW1–6 were found to bind to the polyQ
region while the mAbs MW7 and MW8, were found to bind to the
poly-proline region and the eight last residues in the C-terminal region
of mHTTexon1, respectively. Remarkably, Western blot analysis and
epitope mapping revealed that MW1–6 were found to bind preferen-
tially to the polyQ region of the expanded repeat (mutant) form of
HTT, in contrast to that of the wild-type HTT protein, very similar to
the observations made for two other polyQ binding mAbs 1C2 and 1F8
[117,180,181]. Furthermore, it was found that MW1–6 bind to polyQ
in a linear conformation, consistent with the extended conformation
of the peptide GQ10G observed in the crystal structure of theMW1:pep-
tide complex [182]. Further analysis revealed that MW1–6 poorly
stained nuclear inclusions HD mouse brain sections, in contrast to the
mAbs MW7 andMW8. In addition, remarkable differences in the stain-
ing patterns between sub-cellular compartments of HD mouse brain
sections as well as between HD mice and healthy controls led to the
suggestion that different regions of mHTTexon1 have different solvent
accessibilities, either due to the binding of other sub-cellular speciﬁc
proteins or due to conformational changes of the protein. In a second
1914 E. De Genst et al. / Biochimica et Biophysica Acta 1844 (2014) 1907–1919study, the variable domains of MW1 and 2 were recloned into an scFv
format and assessed for their ability to reduce mHTT cytotoxicity in
human embryonic kidney cells, HEK293 [118]. Very interestingly, it
was found that scFv MW1 and scFv MW2 enhanced mHTT aggregation
and cell-death, results that can be explained by the fact that the anti-
body has a preference for binding to longer and a toxic expanded
polyQ conformation [118]. These results are also consistent with the ef-
fect of a pan-speciﬁc anti-ﬁbrillar scFv, scFv-6E, that also enhances ag-
gregation of mHTT and increased the probability of induced cell-
death in Huntington's disease models [52].
Several antibodies were raised against the C-terminal proline-rich
region of mHTTexon1 [113,117]. This region is believed to be involved
in a number of functions, including endocytosis [183] and interactions
with various transcription factors, including the WW domain proteins
HYPB and HYPC and the splicesome FBP-11 [183], as well as IKKγ, a
regulatory subunit of the IκB kinase complex, and the cell-cycle reg-
ulatory protein P53 [184]. This C-terminal proline-rich region also
has a strong modulating effect on the aggregation of mHTTexon1
in vitro [185]. The fragments of the antibodies that were raised
against this region include the mAb MW7 ad its scFv variant [117];
and the VL domains Happ1 and Happ3, which were all successfully
expressed as intrabodies [113]. The intrabodies Happ1 and Happ3
were also found to very strongly inhibit the aggregation and toxicity
of mHTTexon1, and to increase signiﬁcantly the turnover of the protein,
suggesting that the proline-rich region is important for the stability of
the protein [113].
4.2. Parkinson's disease
PD is the second most common neurodegenerative disorder affect-
ing approximately 1% of the population over the age of 65 [186]. Clinical
symptoms of PD include resting tremor, slowness ofmovement,muscu-
lar rigidity and impairment of postural reﬂex [187]. PD is characterized
neuropathologically by Lewy bodies and Lewy neuritis, which are intra-
cellular inclusions containing ﬁbrils of human aSyn, an intrinsically dis-
ordered, pre-synaptic 140-residue protein that is involved in vesicular
[176] transport and neurotransmitter release [188,189]. There is also
genetic evidence implicating aSyn in the pathogenesis of PD, with
three point mutations (A30P, E46K and A53T) and gene triplication of
aSyn known to cause dominantly inherited early onset PD, and risk
factor polymorphisms in the promoter [188–190]. Despite the clear
presence of aSyn ﬁbrils in the brains of PD patients, it is becoming in-
creasingly evident, as in other neurodegenerative conditions, that
these ﬁbrils are not the most toxic forms of the aggregated protein,
but that instead smaller oligomers are likely to be the more damaging
species [59,191,192].
As with HD, PD is linked to amyloid formation of aSyn that occurs at
least initially inside the cell, and at later stages can spread to neighbor-
ing cells [193]. Cellular, Drosophila and animal models, overexpressing
aSyn, intracellularly accumulate aSyn inclusions and other PD pathology
and various intrabodies targeting aSyn have been evaluated using in situ
models. The intrabody scFv D10 that targets monomeric aSyn and has
been shown to bind intracellularly to aSyn, increasing the soluble frac-
tion of the protein and ameliorating the cell adhesion properties that
are impaired as a result of over-expression and aggregation of aSyn
[103]. In addition, the human VH domain, VH14, and the scFv, NAC32
were selected from a yeast surface display library to bind the relatively
hydrophobic, amyloidogenic region of aSyn, also known as the NAC
region, which is critical for aSyn aggregation (Table 1) [105]. NAC32
was reasonably soluble as an intrabody, and was able to restore cell vi-
ability and reduce signiﬁcantly the cytoxicity by the overexpression the
A53T disease related variant of aSyn in rat neuronal cell lines [105]. The
modiﬁcation of VH14 as a genetic fusion with the PEST proteasomal
degradation signal of mouse ornthine decarboxylase, has been shown
to enhance the efﬁcacy of the intrabody further, a ﬁnding attributable
to the combined effects of the increased solubility of the intrabodyand the increased turnover of aSyn resulting from intrabody binding
[106].
5. Antibody based therapeutic strategies
The major challenge for antibody-based therapies directed at
diseases of the central nervous system (CNS) remains the presence of
the physiological protection of the blood brain barrier (BBB), which
limits the accessibility of most macromolecules to the brain [194].
Some nonspeciﬁc permeability does, however, exist and can be
exploited by using high serum antibody concentrations, which may
also serve as a peripheral sink for the aberrant protein species. Alter-
natively, antibodies can be engineered to incorporate sequences that
have naturally occurring BBB permeability, or they can be engineered to
cross this barrier through active transport either by direct binding to an
endothelial receptor or through fusion to proteins that bind to speciﬁc
receptors for the transport of molecules through the endothelial barrier
[195–198].
Direct delivery of antibodieswithin the brain or spinal cord is amore
invasive but potentially more powerful approach that can be achieved
via injections, pumps, or delivery as genes via viral vectors [199–202].
Antibodies are likely to be effective in dealing with extracellular pro-
teins, including those species that would be responsible for the spread
of pathogenesis through cell-to-cell transmission [193]. There is, how-
ever, evidence from both paraneoplastic neurodegeneration [203,204]
and clearance of intra-neuronal viruseswithout causing damage to neu-
rons that native antibodies can act intracellularly [205]. Genes encoding
binding fragments can also be delivered directly to neurons, with the
protein products acting as intrabodies [5].
AD has been the main focus for immunotherapy for a number of
years [206,207], using both active [208,209] and passive [210] immuni-
zation strategies and some preclinical studies for Parkinson's disease
have also been explored [211–214], and very recently a phase I clinical
trial has been started for the anti-aSyn mAb PRX002 in the US (https://
clinicaltrials.gov/ct2/show/study/NCT02157714).
Whereas active immunization held great promise for AD originally,
clinical trials failed to show signiﬁcant improvement in cognition and
mortality, and presented a great risk of inducing severe inﬂammation
of brain, exacerbating the disease and leading to increased mortality
[207,215,216]. The passive immunization strategies using monoclonal
antibodies have also been extensively explored, with its best-known
candidates, bapineuzumab [217] (manufactured by ELAN) and
solanezumab [218] (manufactured by Lili). Clinical trials using these an-
tibodies, however, showed little or no cognitive efﬁcacy [207], possibly
due to the fact that neurodegeneration was already quite advanced in
the patients well before the start of immunotherapy [212]. The fact
that patients with mild forms of the disease did seem to receive modest
beneﬁts of the immunotherapy with bapineuzumab, shifted focus and
efforts towards treating AD prior to or in the earliest stages of neurode-
generation, however recent phase III clinical trials of immunotherapy
with both bapineuzumab and solanezumab failed to reveal any signiﬁ-
cant improvements in cognitive functions for patients with mild forms
of AD [219,220].
6. Conclusions and future directions
Recent studies are beginning to reveal structural characteristics of
the mechanisms by which soluble peptides and proteins convert into
amyloid ﬁbrils including the nature of the variety of oligomeric species,
populated in such processes, including their roles in toxicity, the man-
ner in which they interact with receptors and membranes. Such infor-
mation provides clues as to possible ways of preventing this aberrant
behavior, perhaps through the discovery of molecules that perturb
individual steps in the mechanism of aggregation. As we discuss here
in this article it is very likely that antibodies will play a key role in
such studies. Their high speciﬁcity and afﬁnitymake themvery selective
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tions, within a mixture of different protein conformers of the aggregat-
ing protein. Moreover, the development of robust antibody fragments
with enhanced functional expression within cells will not only allow
these antibody fragments to be used as research tools and diagnostics,
but will also facilitate their development as powerful therapeutics.
Although antibodies have a very high potential to be used as thera-
peutics for protein misfolding diseases, careful target validation for in-
tervention is clearly needed, and oligomeric species are attractive
candidates, because the protein in its native state should be able to
carry out its normal function. The stabilization of oligomeric species
by binding to the antibody, however, might enhance their formation,
and might be a dangerous strategy to follow. Furthermore, major hur-
dles will need to be overcome in delivery strategies, not least when
the blood brain barrier needs to be crossed to targets that reside in the
cell. These strategies will most probably be disease dependent as the
toxic function of theprotein species formedwill bedependent on the in-
terplay of its levels in the speciﬁc tissue and on its exact location outside
or within the cell.
Also the timing of interventionwill be important. Themajor cause of
neurodegeneration is sporadic and age related and clear outward symp-
toms appear only very late in the disease progression. For this reason
early diagnosis of neurodegenerative conditions is very difﬁcult, which
possibly has contributed to the recent failures of active and passive
immunization strategies to halt disease progression and death, as the
research subjects might have been already in a too advanced stage of
the disease for the therapy to be effective. Therefore biomarker develop-
ment as well as the development of preferably non-invasive methodol-
ogy for early detection of disease onset would be highly beneﬁcial for
the development of effective treatments. Also in this area, antibodies
will probably play a key role as the development of good diagnostic
methods, able to detect disease speciﬁc pathogenic species will most
probably require highly sensitive reagents.
In conclusion, it is clear that great progress is being made in our
understanding of neurodegeneration and reﬁned strategies are being
developed to combat these diseases. A strong role for antibodies is
becoming evident not only in fundamental research of misfolding, but
also in early diagnosis and treatment. It remains to be seen however if
antibody-based therapies will have as high impact as in other medical
applications such as those developed for cancer therapy. The break-
throughs seen for the latter does give rise to strong hopes for equal-
ly effective antibody based therapies to treat neurodegenerative
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